Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pneumococcal 20-valent conjugate vaccine - Pfizer

Next Previous
Drug Profile

Pneumococcal 20-valent conjugate vaccine - Pfizer

Alternative Names: 20vPnC; APEXXNAR; Multivalent Pneumococcal conjugate vaccine - Pfizer; PCV20; PCV20 - Pfizer; PF-06482077; Pneumococcal 20-valent Conjugate Vaccine; Pneumococcal conjugate vaccine - Pfizer; PREVENAR 20; PREVNAR 20

Latest Information Update: 30 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Conjugate vaccines; Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pneumococcal infections
  • Registered Otitis media

Most Recent Events

  • 09 Feb 2026 Pfizer completes a phase II trial in Pneumococcal infections (In Infants, prevention) in the US and Puerto Rico (Parenteral) (NCT06531538)
  • 28 Jan 2026 Pfizer completes a phase I trial in Pneumococcal infections (In adults, In the elderly, Prevention) in China (Parenteral) (NCT07019909)
  • 20 Sep 2025 Pfizer completes a phase III trial in Pneumococcal infections (Prevention, In infants) in India and Taiwan (IM, Injection) (NCT05512819)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top